Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma: A Systematic Review

Author： Auweiler Philipp W.P.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.7, 2012-07, pp. : 537-549

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

By Ray Joshua A.   Carr Emma   Lewis Gavin   Marcus Robert  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 346-357

Blackwell Publishing

Access to resources Recommend Favorite

Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

By Plosker G.L.   Figgitt D.P.  

Drugs, Vol. 63, Iss. 8, 2003-01 ,pp. : 803-843

Adis International

Access to resources Recommend Favorite

Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

By Cvetković Risto S.   Perry Caroline M.  

Drugs, Vol. 66, Iss. 6, 2006-01 ,pp. : 791-820

Adis International

Access to resources Recommend Favorite

Bendamustine: A Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma and Multiple Myeloma

By Hoy Sheridan M.  

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1929-1950

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

By Fagnoni Philippe   Milpied Noel  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 55-68

Adis International

Access to resources Recommend Favorite